Influx Healthtech IPO - details
The Influx Healthtech IPO is scheduled to open on June 18, 2025, and will close on June 20, 2025. This is a Book Built Issue through which the company aims to raise approximately ₹58.57 crores. The offer includes a fresh issue worth ₹48.00 crores and an offer for sale of up to 11,00,400 equity shares, each with a face value of ₹10. The price band for the IPO has been set between ₹91 and ₹96 per share. The allocation breakdown includes 50% for Qualified Institutional Buyers (QIBs), 35% for retail investors, and 15% for High Net-Worth Individuals (HNIs). The basis of allotment is expected to be finalized on June 23, 2025, and the company is likely to list on the NSE on June 25, 2025.
In terms of financial performance, Influx Healthtech posted a revenue of ₹104.99 crores in FY 2025, up from ₹100.10 crores in FY 2024. Net profit also increased to ₹13.37 crores in 2025, compared to ₹11.22 crores in the previous year. Based on its consistent financial growth, the IPO may present a favorable opportunity for investors seeking long-term value.
Influx Healthtech IPO Market Lot Size
The Influx Healthtech IPO minimum market lot is 1200 shares with ₹1,15,200 application amount.
Application | Lot Size | Shares | Amount |
Retail Minimum | 1 | 1200 | ₹1,15,200 |
Retail Maximum | 1 | 1200 | ₹1,15,200 |
S-HNI Minimum | 2 | 2,400 | ₹2,30,400 |
Influx Healthtech IPO Details
IPO Open Date: | June 18, 2025 |
IPO Close Date: | June 20, 2025 |
Face Value: | ₹10 Per Equity Share |
IPO Price Band: | ₹91 to ₹96 Per Share |
Issue Size: | Approx ₹58.57 Crores |
Fresh Issue: | Approx ₹48.00 Crores |
Offer for Sale: | Approx 11,00,400 Equity Shares |
Issue Type: | Book Build Issue |
IPO Listing: | NSE SME |
Retail Quota: | Not more than 35% |
QIB Quota: | Not more than 50% |
NII Quota: | Not more than 15% |
Influx Healthtech IPO Valuation – FY2025 (KPI)
Check Influx Healthtech IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
KPI | Values |
ROE: | 36.98% |
ROCE: | 49.17% |
EBITDA Margin: | 19.62% |
PAT Margin: | 12.75% |
Debt to equity ratio: | 0.01 |
Earning Per Share (EPS): | ₹7.36 (Basic) |
Price/Earning P/E Ratio: | N/A |
Return on Net Worth (RoNW): | 36.98% |
Net Asset Value (NAV): | ₹19.91 |
Influx Healthtech IPO Company Financial Report
In FY 2025, the company recorded a revenue of ₹104.99 crores, reflecting an increase from ₹100.10 crores in FY 2024. Net profit also grew, reaching ₹13.37 crores compared to ₹11.22 crores in the previous financial year.
Period Ended | Revenue | Expense | Profit After Tax | Assets |
2023 | ₹76.06 | ₹66.32 | ₹7.20 | ₹28.30 |
2024 | ₹100.02 | ₹85.08 | ₹11.13 | ₹41.10 |
2025 | ₹104.99 | ₹87.11 | ₹13.37 | ₹70.30 |
Influx Healthtech IPO Dates
Influx Healthtech’s IPO will open for subscription on June 18 and close on June 20. Share allotment is expected to be finalized on June 23, with the listing scheduled for June 25.”
IPO Open Date: | June 18, 2025 |
IPO Close Date: | June 20, 2025 |
Basis of Allotment: | June 23, 2025 |
Refunds: | June 24, 2025 |
Credit to Demat Account: | June 24, 2025 |
IPO Listing Date: | June 25, 2025 |
Promoters of Influx Healthtech IPO
The promoters of the company are Mr. Munir Abdul Ganee Chandniwala, Mrs. Shirin Munir Ahmed Chandniwala and Mr. Abdul Ganee Abdul Rasul Chandniwala.
About Influx Healthtech IPO
Influx Healthtech Limited, established in 2020, is a fast-growing healthcare company with a strong focus on contract manufacturing. It operates as a Contract Development and Manufacturing Organization (CDMO), providing end-to-end solutions to clients across a range of sectors. The company has built its manufacturing infrastructure in Thane, Maharashtra, spanning three facilities of approximately 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft.
Known for maintaining high standards in safety, quality, and regulatory compliance, Influx Healthtech offers manufacturing services in diverse categories—including dietary and nutritional supplements, ayurvedic and herbal products, cosmetics, veterinary feed supplements, and homecare solutions. Its client portfolio includes several prominent names such as Bling Brands, Pursuit of Wellness, Aarkios Health, HSHS Nutraceuticals Limited, Novus Life Science, Bruder Life Science, Fredun Pharmaceuticals, and BigFlex Lifescience. The company currently employs 165 full-time staff members.
Peer Group Comparison
Company | EPS | PE Ratio | RoNW % | NAV | Income |
Sudarshan Pharma Industries Limited | 0.66 | 48.28 | 12.45% | 5.30 | 505.38 Cr. |
Quest Laboratories Limited | 8.28 | 10.38 | 16.58% | 49.92 | 108.16 Cr. |
Objects of the IPO
To finance the setup of a new manufacturing facility dedicated to the Nutraceutical Division
To support capital investments for establishing a Veterinary Food manufacturing unit
To procure machinery and equipment for the Homecare and Cosmetic Division
For general business and corporate needs
Merchant Bankers
- Rarever Financial Advisors Pvt. Ltd. Pvt. Ltd.
Company Address
Influx Healthtech Limited
109, Ghanshyam Enclave Premises Co-op
Soc Plot No. 856, Laljipada
Kandivali West,
Mumbai, Maharashtra
Phone: +91 7045997809
Email: [email protected]
Website: https://influxhealthtech.com/
Influx Healthtech IPO Registrar
Maashitla Securities Private Limited
Phone: +91-11-45121795-96
Email: [email protected]
Website: https://maashitla.com/allotment-status/public-issues